Molecular Templates Provides Corporate Update and Outlines 2018 Milestones
Molecular Templates, Inc. (MTEM)
Last molecular templates, inc. earnings: 11/12 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.mtem.com/investor-relations
Company Research
Source: GlobeNewswire
Takeda Nominated Two Targets Under Research Collaboration in Dec. 2017 Updated MT-3724 Clinical Results Expected in 1H18 At Least Two New MTEM Products to Enter the Clinic in 2018 AUSTIN, Texas, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today provided a review of 2017 company progress as well as an update on expected 2018 milestones. “2017 was a transformational year for Molecular Templates as we became a publicly traded company, raised $60 million from institutional investors and our partner Takeda Pharmaceuticals, made important clinical progress with our lead pipeline program MT-3724, and expanded and advanced our collaboration with Takeda,” said Eric Poma Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates.
Show less
Read more
Impact Snapshot
Event Time:
MTEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MTEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MTEM alerts
High impacting Molecular Templates, Inc. news events
Weekly update
A roundup of the hottest topics
MTEM
News
- Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer PatieAcquire Media Monitor
- Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer PatieGlobeNewswire
- Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business UpdateGlobeNewswire
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement [Yahoo! Finance]Yahoo! Finance
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase AgreementGlobeNewswire
MTEM
Earnings
- 11/13/23 - Beat
MTEM
Sec Filings
- 4/25/24 - Form S-3
- 4/25/24 - Form 10-K/A
- 4/12/24 - Form 8-K
- MTEM's page on the SEC website